Akcea Retains Rights to AKCEA-APOCIII-LRx

Data from Phase 2 clinical trial of AKCEA-APOCIII-LRx anticipated in early 2020 BOSTON and CARLSBAD, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ: AKCA), a majority-owned affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that, following a strategic portfolio decision by Novartis not to exercise its option, Akcea has retained rights to develop and commercialize AKCEA-APOCIII-LRx.

The release as fetched from its publisher. ionis.com ↗